BioCentury | Oct 21, 2020
Deals

Oct. 21 Quick Takes: Clear path for BMS in MyoKardia deal; plus WuXi Biologics rises, Purdue settles, Actemra, Cara-Vifor and more

...COVID-19 miss by an IL-6 inhibitor, Actemra tocilizumab...
BioCentury | Sep 18, 2020
Product Development

Genentech finds right endpoint to show IL-6 benefit in COVID-19

...unit of Roche (SIX:ROG; OTCQX:RHHBY) said Friday that the Phase III EMPACTA trial of Actemra tocilizumab...
...are secondary endpoints. TARGETSIL-6 – Interleukin-6 Stephen Hansen RoActemra (Brand), Actemra (Brand), RG1569 (Compound #), R1569 (Compound #), tocilizumab...
BioCentury | Sep 16, 2020
Product Development

COVID-19 Quick Takes: secondary consequences of COVID-19 in children; plus BioNTech receives funding and expands trial, Regeneron enters RECOVERY, Valneva and Novavax

...three other potential COVID-19 treatments — azithromycin, tocilizumab...
...Brand), RG1569 (Compound #), R1569 (Compound #), tocilizumab...
BioCentury | Sep 15, 2020
Product Development

Lilly’s Olumiant adds to remdesivir benefit in NIH COVID-19 study

...ventilation. Dexamethasone’s success had contrasted sharply with July’s Phase III disappointments for anti-IL-6 mAbs Actemra tocilizumab...
BioCentury | Sep 10, 2020
Product Development

Oxford’s Landray wants RECOVERY-type trials to go well beyond COVID-19: a BioCentury audio interview

...actually donated drugs -- so Roche donated tocilizumab...
...And particularly -- take the example of tocilizumab...
...more patients randomized in recovery trial to tocilizumab...
BioCentury | Sep 4, 2020
Product Development

CEOs pledge rigorous Phase III testing for COVID-19 vaccines

...CEO Severin Schwan noted that the Phase III failures of IL-6 inhibitors including Roche’s Actemra tocilizumab...
BioCentury | Aug 6, 2020
Product Development

Warp Speed makes J&J COVID-19 vaccine program fifth above $1B

...Phase III in September. IL-6 86’d BARDA has stopped supporting development of anti-IL-6 mAbs Actemra tocilizumab...
...#), REGN88 (Compound #), sarilumab (Generic) RoActemra (Brand), Actemra (Brand), RG1569 (Compound #), R1569 (Compound #), tocilizumab...
BioCentury | Aug 1, 2020
Product Development

Will Biocon’s COVID-19 anti-inflammatory succeed where IL-6 blockers have failed?

...common side effect of treatment with CAR T therapies, and IL-6 inhibitors such as Actemra tocilizumab...
BioCentury | Jul 30, 2020
Product Development

Finding immunosuppression sweet spot could be next up for COVID-19 after second IL-6 failure

...rather than targeting that specific cytokine -- may offer a more effective treatment. Actemra tocilizumab...
...Interleukin-6 Elizabeth S. Eaton, Staff Writer RoActemra (Brand), Actemra (Brand), RG1569 (Compound #), R1569 (Compound #), tocilizumab...
BioCentury | Jul 2, 2020
Product Development

First Phase III data for an IL-6 mAb in COVID-19 disappoint

...has disappointed -- failing a previous trial in severe patients -- another anti-IL-6 mAb, Actemra tocilizumab...
Items per page:
1 - 10 of 245